EMA Refused: Acrescent (memantine hydrochloride;donepezil hydrochloride) — H. Lundbeck A/S

View source ↗

Summary

EMA refused the Acrescent (memantine hydrochloride; donepezil hydrochloride) application for Alzheimer’s disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Acrescent (memantine hydrochloride; donepezil hydrochloride)

Snippet

Status: Refused. Therapeutic area: Alzheimer Disease. MAH: H. Lundbeck A/S. Decision date: 18/10/2012